Global Antibiotic Research & Development Partnership:
A recent research carried out by Global Antibiotic Research and Development Partnership (GARDP) has revealed that a significant number of multidrug-resistant infections in low- and middle-income countries (LMICs), including India, are not being treated appropriately, because of large gaps in access.
- It is a not-for-profit organization that develops new antibiotic treatments for drug-resistant bacterial infections that pose the greatest threat to human health and makes them accessible to the people who need them.
- It puts public health needs at the centre of antibiotic drug development to address both the immediate antimicrobial resistance (AMR) crisis and to ensure people continue to get access to essential antibiotics for generations to come.
- GARDP was created by the World Health Organization (WHO) and Drugs for Neglected Diseases initiative (DNDi) to deliver on the Global Action Plan on AMR (2015), which underscores the need for new initiatives to develop novel antibiotic treatments.
- Legally established as an independent foundation in Geneva, Switzerland, in 2018, GARDP responds to the urgent need for antibiotic research, development, and access.
- It brings together public and private partners to accelerate the development and global availability of new antibiotics.
